The methyl-CpG-binding protein MeCP2 has been reported to bind to methylated CpG motifs [30] in CRE sites, which may block binding of other factors.
Targeting C4BP binding sites on bacterial surfaces with vaccine-induced antibodies may block binding of C4BP and enhance a common vaccine design strategy that depends on the generation of complement-dependent bactericidal and opsonophagocytic antibody activities.
Surface features of the CRD near to the binding site may block binding of some ligands, particularly those with fixed geometry such as the Lewisx structure, rather than enhance binding through favorable interactions.
In general, bromodomain inhibitors may block the binding interactions of many different protein ligands, often complicating analysis of single ligand interactions in cells.
Hence, Thr51 phosphorylation may block pHP1γS93 binding to the chromatin via H3K9me3, shifting the HP1γ function from heterochromatin formation and gene silencing to euchromatic gene expression.
In our initial attempt to screen small molecules that may block MDM2/MDMX p53 binding, we surprisingly identified a novel small molecule called INZ that effectively activates p53 by inhibiting SIRT1 activity without genotoxicity.
In cells that do not normally express PRH, such as T-cells, T-cell-specific proteins may block the binding of PRH to growth-control proteins such as eIF-4E or promote other unknown interactions that allow increased proliferation or decreased apoptosis, resulting in T-cell leukaemias.
Because CpG methylation is thought to block binding of transcription factors, we mutated those five CpG dinucleotides to TpG dinucleotides, which may also block binding of such transcription factors.
Methyl-CpG binding proteins (MBPs), including methyl-CpG binding protein 2 (MeCP2) and methyl-CpG binding domains (MBD1, MBD2, MBD3, and MBD4), may block transcription factor binding to DNA by recruiting chromatin remodeling corepressor complexes [18], [19].
UK4VLCDR1, however, does not block binding.
Based on our results with PF74 at the lower concentration, we speculated that PF74 may block the CPSF6 binding interface on CA at this concentration, and may thus lead to a loss of CPSF6 association with cytoplasmic RTC/PIC.
